Mixed findings on safety of Warfarin and Pradaxa

More mixed findings have emerged from the latest comparison of the safety profiles of Warfarin and Pradaxa (dabigatran).

A US Food and Drug Administration (FDA) observational cohort study directly comparing the two drugs’ impact on a range of outcomes, has found Pradaxa lowers the risk of stroke and of mortality, but increases the risk of gastrointestinal bleeds when compared to Warfarin.

There were 34.2 major GI bleeds per 1000 person years with Pradaxa, compared to 26.5